https://orcid.org/0000-0002-4306-3242
References
- Suárez Ferrer C, González-Lama Y, González-Partida I, et al. Usefulness of thiopurine monotherapy for Crohn's disease in the era of biologics: a long-term single-center experience. Dig Dis Sci. 2019;64(3):875–879.
- Stournaras E, Qian W, Pappas A, et al. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Gut. 2021;70(4):677–686.
- Verstockt B, Boets L, Sabino J, et al. Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease. Gut. 2021;70(7):1416–1418.
- Thomsen SB, Allin KH, Burisch J, et al. Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: a nationwide Danish cohort study. United European Gastroenterol J. 2020;8(1):68–76.
- Khan N, Abbas A, Lichtenstein G, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013;145(5):1007–1015.
- Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;40(4):338–353.
- Lee JM, Kim YJ, Lee K-M, et al. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease. Scand J Gastroenterol. 2018;53(10–11):1280–1285.
- Verstockt B, Moors G, Bian S, et al. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. Aliment Pharmacol Ther. 2018;48(7):731–739.
- Kennedy NA, Kalla R, Warner B, et al. Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Aliment Pharmacol Ther. 2014;40(11–12):1313–1323.
- Iborra M, Herreras J, Boscá-Watts MM, et al. Withdrawal of azathioprine in inflammatory bowel disease patients who sustain remission: new risk factors for relapse. Dig Dis Sci. 2019;64(6):1612–1621.
- Doherty G, Katsanos KH, Burisch J, et al. European Crohn's and colitis organisation topical review on treatment withdrawal [‘exit strategies’] in inflammatory bowel disease. J Crohns Colitis. 2018;12(1):17–31.
- Pittet V, Froehlich F, Maillard MH, et al. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel. J Crohns Colitis. 2013;7(10):820–826.
- Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63–70.
- Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–1625.
- Drobne D, Bossuyt P, Breynaert C, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2015;13(3):514–521.
- Lobatón T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42(4):441–451.
- Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49(7):873–879.